Compositions and methods for directing proteins to specific loci in the genome
AssigneePoseida Therapeutics, Inc.
InventorsEric M. Ostertag, Tseten Yeshi, Xianghong Li
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a fusion protein comprising a DNA localization component and an effector molecule. Preferred embodiments of the disclosure include, but are not limited to, the following fusion proteins: dSaCas9-Clo051, dCas9-Clo051, Xanthomonas-TALE-Clo051, and Ralstonia-TALE-Clo051.
Claims13
A method for directing proteins to specific loci in a genome of an organism comprising contacting a genomic DNA sequence with a composition comprising a DNA localization component and an effector molecule, or a nucleic acid encoding the DNA localization component and the effector molecule,
- (a) wherein the DNA localization component comprises at least one guide RNA (gRNA), and
- (b) wherein the effector molecule comprises a fusion protein, wherein the fusion protein comprises (i) an inactivated Cas9 (dCas9) or an inactivated nuclease domain thereof and (ii) Clo051 or a nuclease domain thereof.
A method for modifying a genome of at least a cell of an organism comprising contacting a genomic DNA sequence with a composition comprising a DNA localization component and an effector molecule, or a nucleic acid encoding the DNA localization component and the effector molecule,
- (a) wherein the DNA localization component comprises at least one guide RNA (gRNA), and
- (b) wherein the effector molecule comprises a fusion protein, wherein the fusion protein comprises (i) an inactivated Cas9 (dCas9) or an inactivated nuclease domain thereof and (ii) Clo051 or a nuclease domain thereof.
A composition comprising a DNA localization component and an effector molecule,
- (a) wherein the DNA localization component comprises at least one guide RNA (gRNA), and
- (b) wherein the effector molecule comprises a fusion protein, wherein the fusion protein comprises (i) an inactivated Cas9 (dCas9) or an inactivated nuclease domain thereof and (ii) Clo051 or a nuclease domain thereof.
Dependencies are inferred from the claim text.